UK sues Reckitt after heartburn market probe; FDA orders safety trials on LABAs;

@FiercePharma: Warner Chilcott plots 500 job cuts in European revamp. Item | Follow @FiercePharma

> The National Health Service has sued Reckitt Benckiser for £90 million, following an investigation that ruled the group had abused its dominant position in the UK heartburn market. Report

> Pain treatment developer Nuvo Research has agreed to buy specialty drugmaker ZARS Pharma for about $12.2 million in shares and a possible $14.9 million or more top-up. News

> The FDA has ordered drugmakers to conduct clinical trials involving a total of 53,000 patients to test the safety of long-acting beta-agonists (LABAs), a controversial class of inhaled asthma drugs sold by AstraZeneca, GlaxoSmithKline, Merck and Novartis. Item

> Novartis has sued AstraZeneca's MedImmune unit and a UK-financed research agency in a bid to revoke a patent extension for a drug manufacturing process used to make the active ingredient in its eye drug Lucentis. Article

> AstraZeneca is set to break off its $1.4 billion, seven-year IT outsourcing relationship with IBM, planning to end the relationship in 12-15 months, Computerworld reports. Report

> Ranbaxy Laboratories is expected to play a significant role in parent company Daiichi Sankyo's growth plans in the Chinese generics market, in addition to Japan, as both companies leverage opportunities from their hybrid business model. Story

> Drugmakers should invest in public health campaigns as a way to improve trust in the industry and help with the challenges facing healthcare systems, a new report suggests. News

> The U.S. Supreme Court took no action on a request to speed up a ruling on President Barack Obama's healthcare overhaul law. Report

Biotech News

 @FierceBiotech: Regulators hand Eli Lilly another new drug rejection. Item | Follow @FierceBiotech

 @JohnCFierce: Domain Associates, GBS Venture Partners and BioPacificVentures hand CoDa Therapeutics a $19M Series B. Story | Follow @JohnCFierce

> Circassia lands $98M venture round as it plots Ph3 trials. Article 

> Chatter: Top biotech analyst selects list of likely takeover targets. Story 

> Novartis yanks European app for pain drug. Item 

> Novartis' Ph3 success advances blockbuster COPD program. Report 

Biotech Research News

> Stem cells from schizophrenics show how neurons make fewer connections. Story

> Parents surveyed would want gene tests for kids. News

> Science of addiction could offer alternatives to punishment of addict. Item 

> South African center to focus on regional drug-development needs. Report 

> Australia sees a gap in cancers represented in clinical trials. Story

> 'Accelerated evolution' gene could help predict preterm births. Article

Manufacturing News

> FDA achievements overlooked by critics. Story 

> Manufacturing cost gap closing among U.S., India, China. Article 

> Report: Pharma manufacturing "best bet" for college grads. News 

> FDA takes another look at cancer drug shortage. Story 

> Risk-based manufacturing gains steam at PDA. Report 

> Stirling cranks up Canada plant with tablet job. Item

And Finally... Up to 200,000 deaths from malaria could be averted each year if countries switched to a more expensive but more effective drug, Medecins Sans Frontieres said. Report

Suggested Articles

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.

A patent decision in Delaware clears the way for multiple generic companies to launch their Tecfidera copycats—and target its $3.3B in U.S. sales.

Sanofi and GlaxoSmithKline signed a deal with the EU to supply up to 300 million doses of their recombinant protein-based COVID-19 vaccine.